Annexon Inc
Company Profile
Business description
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.
Contact
1400 Sierra Point Parkway
Suite 200, Building C
BrisbaneCA94005
USAT: +1 650 822-5500
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
100
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,574.60 | 49.80 | 0.58% |
| CAC 40 | 7,883.63 | 3.06 | -0.04% |
| DAX 40 | 23,934.98 | 167.55 | 0.70% |
| Dow JONES (US) | 42,792.07 | 137.33 | 0.32% |
| FTSE 100 | 8,699.31 | 14.75 | 0.17% |
| HKSE | 23,505.72 | 173.00 | 0.74% |
| NASDAQ | 19,215.46 | 4.36 | 0.02% |
| Nikkei 225 | 37,717.21 | 218.58 | 0.58% |
| NZX 50 Index | 12,643.15 | 14.08 | 0.11% |
| S&P 500 | 5,963.60 | 5.22 | 0.09% |
| S&P/ASX 200 | 8,346.00 | 50.90 | 0.61% |
| SSE Composite Index | 3,373.49 | 5.91 | 0.18% |